CEPHO

Cepho Biotech is a clinical-stage biotechnology company based in Taiwan that focuses on developing long-acting therapeutics for ophthalmic diseases. The company's lead program, CPH-001, is a long-acting anti-VEGF agent aimed at treating retinal conditions such as wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). By utilizing a proprietary protein engineering platform, Cepho aims to extend the duration of drug effect, significantly reducing the burden of frequent intravitreal injections for patients. The company was spun out from the Industrial Technology Research Institute (ITRI) to commercialize advanced drug delivery and protein stabilization technologies. Cepho's approach addresses a significant unmet need in the ophthalmology market by improving patient compliance and long-term visual outcomes through sustained-release biologics.